836株铜绿假单胞菌的临床分布及耐药性分析

目的分析铜绿假单胞菌在临床标本中的分布特点及其对常用抗菌药物的耐药性。方法常规分离菌株,采用最低抑菌浓度(MIC)法进行抗菌药物敏感性试验,根据美国临床标准化委员会(CLSI)2014标准采用WHONET5.6软件、MDR-1.03软件和SPSS 19.0软件进行统计分析。结果临床分离的836株铜绿假单胞菌主要来自痰液(73.56%),神经外科检出率最高(30.38%)。铜绿假单胞菌对阿米卡星的耐药率最低(5.26%),对氨基糖苷类、喹诺酮类抗菌药物、头孢他啶、头孢吡肟、哌拉西林他唑巴坦、亚胺培南的敏感性较好(68.06%~90.07%),对其余药物敏感性小于60%;其中多重耐药及泛耐药铜绿假单胞菌检出率分别为41.39%和3.35%。结论铜绿假单胞菌对抗菌药物的耐药率仍处于较高水平,但近年耐药率增长趋势稳定,且具有多重耐药性。     

创伤外科62株铜绿假单胞菌体外抗菌药物敏感性分析

目的了解创伤外科铜绿假单胞菌对亚胺培南等12种抗菌药物的抗菌活性,指导临床合理用药。方法利用WHONET软件对62株创伤外科分离的铜绿假单胞菌药敏试验结果进行统计和分析。结果铜绿假单胞菌对阿米卡星敏感性最高(96.77%),依次为哌拉西林/他唑巴坦、亚胺培南、哌拉西林、庆大霉素、妥布霉素、左旋氧氟沙星,敏感率分别为87.10%、72.58%、70.97%、70.60%、69.35%、66.13%。敏感率小于60%抗菌药物分别是头孢他啶、氨曲南、头孢吡肟、环丙沙星、替卡西林/克拉维酸。痰标本中的铜绿假单胞菌对抗菌药物的敏感率均小于分泌物中的铜绿假单胞菌。结论创伤外科铜绿假单胞菌对多种抗菌药物保持较高的敏感性;铜绿假单胞菌对抗菌药物的耐药性呈现逐年增加的趋势。     

慢性化脓性中耳炎的病原学、药敏试验及其毒力基因分析

目的分析慢性化脓性中耳炎(CSOM)病原学的近阶段变化和药敏试验结果,研究金黄色葡萄球菌和铜绿假单胞菌的毒力基因。方法选取166例CSOM患者(179只患耳),采集其中耳鼓室分泌物进行细菌和真菌培养,使用安图MS1000质谱仪、生物梅里埃公司的Vitec 2微生物鉴定药敏分析系统和Vitec Densichek比浊仪等进行细菌鉴定和药敏试验。采用PCR方法对经分离鉴定的金黄色葡萄球菌和铜绿假单胞菌所携带的毒力基因进行分别检测。结果 166例患者(179只患耳)的标本中,132例患者(143只患耳)培养出致病菌,检出率为79.89%(143/179)。共培养出167株致病菌,排名前三位的分别是金黄色葡萄球菌(29.94%,50/167)、丝状真菌(26.35%,44/167)、铜绿假单胞菌(7.19%,12/167)。药敏试验:革兰阳性菌81株,占48.50%,其中金黄色葡萄球菌50株(占29.94%),对青霉素G的耐药率最高为90.00%;革兰阴性菌22株,占13.17%,对环丙沙星和左旋氧氟沙星耐药率最高均为25.00%。金黄色葡萄球菌的毒力基因中HLα基因检出率最高,铜绿假单胞菌的毒力基因中ToxA的检出率最高,均为100%。结论金黄色葡萄球菌的HLα基因和铜绿假单胞菌的ToxA基因与其致病性密切相关。致病菌的培养鉴定、药敏试验分析及其毒力基因的检测,定期总结本地区CSOM的主要病原菌的动态变化,可为合理用药提供科学参考,并促进临床个体化、精准化治疗。     

慢性化脓性中耳炎的病原菌及耐药性分析

目的 研究慢性化脓性中耳炎主要病原菌的种类及对抗生素的耐药情况。方法对98例慢性化脓性中耳炎患者的耳分泌物进行细菌培养,对分离的病原菌进行药物敏感试验。结果分离出病原菌103株,以金黄色葡萄球菌(38株)和铜绿假单胞菌(33株)为主,金黄色葡萄球菌对青霉素和红霉素的耐药率分别为100％和66％,对氨基糖甙类、氟喹诺酮类敏感性较高;铜绿假单胞菌对氨苄西林、头孢类抗生素耐药率较高,对氟喹诺酮类、氨基糖甙类抗生素敏感。结论 金黄色葡萄球菌和铜绿假单胞菌是青岛地区慢性化脓性中耳炎的主要致病菌,二者对青霉素类抗生素有较高的耐药率。临床医师不能仅凭经验,而应根据细菌培养和药敏结果用药,以防耐药菌株产生。     

西安地区290例儿童急性中耳炎分泌物细菌培养及药敏分析

目的探讨西安地区儿童急性中耳炎分泌物细菌培养及药物敏感试验。方法选取2014年1~6月该院就诊的290例急性中耳炎患儿分泌物常规细菌培养及常用药物敏感性试验。结果 290例患儿共分离出病原菌267株,包括革兰阳性球菌150株,占56.18%,其主要由金黄色葡萄球菌、肺炎链球菌及凝固酶阴性葡萄球菌等构成;革兰阴性杆菌94株,占35.21%,其主要由铜绿假单胞菌、肺炎克雷伯菌、流感嗜血杆菌、奇异变形杆菌、大肠埃希菌等构成;真菌占6.74%,主要为念珠菌属。结论该地区儿童急性中耳炎的常见致病菌为金黄色葡萄球菌、肺炎链球菌、凝固酶阴性葡萄球菌、铜绿假单胞菌。不同种类病原菌对抗菌药物的敏感性及耐药性不同,可用于指导临床合理有效使用抗菌药物,提高临床治愈率。     

慢性化脓性中耳炎的病原菌分布及耐药性分析

目的探讨慢性化脓性中耳炎(chronic suppurative otitis media,CSOM)的病原菌分布及对抗生素的耐药情况,以指导临床合理用药。方法对165例(214耳)单纯型CSOM患者在确诊后24h内采集鼓膜穿孔处或鼓室内分泌物进行细菌培养及鉴定,并对分离的主要病原菌进行药物敏感试验。结果 165份标本共分离出病原菌245株,其中G+菌69株(28.16%),G-菌149株(60.82%),真菌27株(11.02%)。金黄色葡萄球菌对阿莫西林、哌拉西林、青霉素的耐药率均>50%,铜绿假单胞菌对阿奇霉素、阿莫西林、红霉素、头孢唑啉、哌拉西林及青霉素的耐药率均>50%,肺炎克雷伯杆菌对亚胺培南、头孢他啶、头孢西丁、头孢唑啉及青霉素的耐药率均>50%,大肠埃希菌对左氧氟沙星、环丙沙星、庆大霉素、头孢他啶、头孢西丁、阿莫西林及青霉素的耐药率均>50%,鲍曼不动杆菌对15种常用抗生素的耐药率均<50%。结论 G-菌是CSOM的主要致病菌,治疗应根据致病菌及药物敏感试验选择合适的药物。     

小儿迁延性和慢性腹泻病病原体及抗生素敏感性变迁10年研究

目的：探讨儿科迁延和慢性腹泻病（PCDD）病原体及主要致病菌对常用抗生素敏感性的变迁，方法：对近10年来PCDD与急性腹泻病（ADD）各种病原体检出率进行比较，对PCDD常见病原体检出率及抗生素敏感率进行逐年统计，并进行前后5年比较，结果PCDD组白色念珠菌、变形杆菌属、枸橼酸杆菌，铜绿假单胞菌、沙雷杆菌、金黄色葡萄球菌，耶尔森菌。新型隐球菌，难辨梭状芽胞杆菌及肠道毛滴虫、溶组织阿米巴原虫、隐孢子虫等检出率较高。而ADD组轮状病毒。肠毒性大肠杆菌，志贺氏菌属检出率较高。PCDD组条件致病，菌检出率逐渐增高，而原虫检出率则逐渐降低。细菌对常用抗生素敏感率逐渐降低，前后5年比较白色念珠菌，变形杆菌属、枸橼 菌属、肠道毛滴虫检出率有显著性差异（P＜0．05），溶组织阿米巴原虫检出率有非常显著性差异（P＜0．01），青霉素、氨苄青霉素、头孢唑啉、氯霉素、大霉素敏感率有显著性差异（P＜0．05），而头孢三嗪、胺卡那霉素、氟哌酸，环丙沙星敏感率无显著性差异（P＜0．05）。结论PCDD近10年来条件致病菌染渭增,是原虫感染则逐渐降低。细菌对常用抗生素敏感率逐渐降低，但对头孢三嗪，丁胺卡那霉素、氟哌酸，环丙沙星敏感率下降不明显。     

黏液型铜绿假单胞菌K-B法与MIC法药敏试验结果的比较

目的探讨黏液型铜绿假单胞菌K-B法与MIC法药敏试验结果的差异。方法对该院2015年1-12月住院患者培养出的72株黏液型铜绿假单胞菌同时进行K-B法和MIC药敏试验,在35℃培养48h后读取结果,K-B法手工正确测量抑菌环直径,MIC法用ATB细菌鉴定仪进行读取。结果两种方法的检测中,除全耐药的复方磺胺甲噁唑、氨苄西林/舒巴坦两种全耐药外,黏液型铜绿假单胞菌对阿米卡星、美罗培南、亚胺培南、庆大霉素、妥布霉素、哌拉西林/他唑巴坦、头孢派酮/舒巴坦的敏感性两种方法相差小于5%,其余结果相差在10%左右,MIC法普遍比K-B法敏感性高。在黏液型铜绿假单胞菌对阿米卡星、妥布霉素、头孢派酮/舒巴坦敏感性较好,敏感率为88%~96%,对其余抗菌药物的敏感率为50%~80%。结论 K-B法在检测黏液型铜绿假单胞菌对抗菌药物的敏感性比MIC法更稳定、更可靠。在日常检测工作中选择K-B法检测更合适。     

耐环丙沙星铜绿假单胞菌的临床分离及耐药性分析

目的了解宿迁地区耐环丙沙星铜绿假单胞菌的临床分离及药物敏感情况。方法用德国西门子公司AutoScan4微生物鉴定和药敏系统对90株铜绿假单胞菌进行鉴定和药敏检测,其中耐环丙沙星铜绿假单胞菌（耐药菌株）40株,环丙沙星敏感铜绿假单胞菌（敏感菌株）50株。对,临床常用抗菌药物的药敏情况进行分析。结果在临床常用的抗菌药物中,耐药株对哌拉西林／他唑巴坦的敏感率最高为70．0％,另外敏感率大于50．0％的还有阿米卡星（60．0％）和哌拉西林（55．0％）;耐药株较敏感株对9种抗菌药物的敏感性明显降低,其差异具有统计学意义（P〈0．05）。结论耐环丙沙星铜绿假单胞菌对临床常用抗菌药物的敏感性降低,并呈多重耐药,对其引起的感染,哌拉西林／他唑巴坦和阿米卡星、哌拉西林,可作为对经验性治疗的首选药物。     

113例病灶分泌物真菌分布及药物敏感试验结果

目的 分析113例病灶分泌物真菌分布及药物敏感试验结果,更好地为临床提供确切的治疗药物。方法 收集113例真菌感染病灶分泌物标本,对其进行真菌鉴定及药物敏感试验。结果 113例真菌感染病灶分泌物标本中,白色念珠菌75株(66.4%),都柏林念珠菌29株(26.7%),近平滑念珠菌6例(5.3%),克柔念珠菌3例(2.7%)。5-氟胞嘧啶和两性霉素B对白色念珠菌的敏感度较高,分别为94.7%和97.3%;两性霉素B对都柏林念珠菌的敏感率为93.1%;伏立康唑和两性霉素B对近平滑念珠菌的敏感率均为83.3%;5-氟胞嘧啶和两性霉素B对克柔念珠菌的敏感率均为100.0%。结论 加强用药前病灶分泌物的真菌培养和药物敏感试验,合理应用抗菌药物有助于患者的治疗。     

In vitro susceptibility studies with oxiconazole (Ro 13-8996)

Oxiconazole (Ro 13-8996) is a recently described imidazole derivative intended for topical use. 128 isolates of pathogenic fungi were tested in vitro against oxiconazole, miconazole, and ketoconazole using an agar dilution method. Results indicated that miconazole was markedly more active than either oxiconazole or ketoconazole against Candida albicans while ketoconazole was the more active compound against Candida parapsilosis. A species specific difference in the susceptibilities of isolates of Aspergillus fumigatus and Aspergillus flavus to all three imidazoles with A. flavus being more susceptible was noted. Both Mucor and Rhizopus were more susceptible to oxiconazole than to either miconazole or ketoconazole. There were no noticeable differences among the dermatophytes in tests with the three drugs with all geometric mean minimum inhibition concentrations (MIC) being less than 1.0 micromilligram-1. The dematiaceous fungi also demonstrated no major differences in susceptibility to the three drugs. One isolate of Pseudallescheria boydii was relatively resistant to all three drugs (MIC greater than or equal to 16 micromilligrams-1).     

外科ICU院内感染的病原菌及其耐药性分析

目的了解外科ICU内引起院内感染的主要病原菌及其耐药性,为临床合理用药提供依据。方法回顾性分析中山大学附属第三医院2010年1月至2014年5月确定为ICU院内感染137例患者的感染病原菌及其耐药性。结果137例患者中分离出感染病原菌223株。病原菌中革兰阴性杆菌最多,为120株,占53．8％,前三位分别为鲍曼不动杆菌、铜绿假单胞菌、肺炎克雷伯菌;革兰阳性球菌41株,占18．4％,前三位分别为金黄色葡萄球菌、屎肠球菌、溶血葡萄球菌;真菌62株,占27．8％,前三位分别为白色念珠菌、光滑念珠菌、季也蒙假丝酵母菌。耐药性结果显示革兰阴性杆菌耐药性鲍曼不动杆菌呈现多重耐药或泛耐药趋势,铜绿假单胞菌对碳青霉烯类药物的耐药性普遍升高,而敏感性降低,肺炎克雷伯菌表现了相对于鲍曼不动杆菌及铜绿假单胞菌较好的敏感性及较低的耐药性。阳性菌菌株及真菌菌株对药物的敏感性下降,耐药性上升,但目前尚未发现对万古霉素及利奈唑胺耐药的阳性菌株及对两性霉素B耐药的真菌菌株。结论该ICU的院内感染中以革兰阴性杆菌为主,鲍曼不动杆菌、铜绿假单胞菌、肺炎克雷伯菌为主要构成菌,耐甲氧西林金黄色葡萄球菌（MRSA）和真菌的感染比例也较高,且耐药性严重。     

Symposium on infections in the compromised host. The leukemias

The treatment of acute leukemia in the adult causes prolonged and profound granulocytopenia. When the patient has less than 100 granulocytes per microliter, the risk of life-threatening infection is extremely high. Major infections include bacteremia, pneumonia, pharyngitis, esophagitis, colitis, perianal or perirectal lesions, and cellulitis. The major organisms are gram-negative bacilli (especially Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae), gram-positive organisms (Staphylococcus epidermidis and Staphylococcus aureus), the yeasts (Candida albicans and Torulopsis glabrata), and the filamentous fungi (Aspergillus flavus and fumigatus). Infection prevention includes the return to normal of the patient's host defense mechanisms, reduction of invasive procedures which breach body barriers, and methods to decrease the acquisition of potential pathogens, and to reduce the number of organisms colonizing the patient.     

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000

Posaconazole, ravuconazole, and voriconazole are new triazole derivatives that possess potent, broad-spectrum antifungal activity. We evaluated the in vitro activity of these investigational triazoles compared with that of itraconazole and amphotericin B against 239 clinical isolates of filamentous fungi from the SENTRY Program, including Aspergillus spp. (198 isolates), Fusarium spp. (7 isolates), Penicillium spp. (19 isolates), Rhizopus spp. (4 isolates), Mucor spp. (2 isolates), and miscellaneous species (9 isolates). The isolates were obtained from 16 different medical centers in the United States and Canada between January and December 2000. In vitro susceptibility testing was performed using the microdilution broth method outlined in the National Committee for Clinical Laboratory Standards M38-P document. Overall, posaconazole was the most active compound, inhibiting 94% of isolates at a MIC of < or = 1 microg/ml, followed by voriconazole (91%), amphotericin B (89%), ravuconazole (88%), and itraconazole (70%). All three new triazoles demonstrated excellent activity (MIC, < or = 1 microg/ml) against Aspergillus spp. (114 Aspergillus fumigatus, 22 Aspergillus niger, 13 Aspergillus flavus, 9 Aspergillus versicolor, 8 Aspergillus terreus, and 32 Aspergillus spp.): posaconazole (98%), voriconazole (98%), ravuconazole (92%), amphotericin B (89%), and itraconazole (72%). None of the triazoles were active against Fusarium spp. (MIC at which 50% of the isolates tested were inhibited [MIC(50)], >8 microg/ml) or Mucor spp. (MIC(50), >8 microg/ml). Posaconazole and ravuconazole were more active than voriconazole against Rhizopus spp. (MIC(50), 1 to 2 microg/ml versus >8 microg/ml, respectively). Based on these results, all three new triazoles exhibited promising activity against Aspergillus spp. and other less commonly encountered isolates of filamentous fungi. The clinical value of these in vitro data remains to be seen, and in vitro-in vivo correlation is needed for both new and established antifungal agents. Surveillance efforts should be expanded in order to monitor the spectrum of filamentous fungal pathogens and their in vitro susceptibility as these new antifungal agents are introduced into clinical use.     

眼科术后感染患者病原菌分布及其药敏性分析

目的研究眼科术后感染患者病原菌的分布情况,并分析其对各抗菌药物的药敏性,为临床及时、合理使用抗菌药物提供医学依据。方法选取2010年2月至2014年12月就诊于本院眼科的术后感染患者60例,通过涂片获得患者眼部病原菌,经革兰染色和药敏试验,针对病原菌的分布进行分析。结果检出的病原菌为革兰阴性菌、革兰阳性菌和真菌。有50.00%患者被检出革兰阳性菌,其中表皮葡萄球菌占21.67%;25.00%的患者被检出革兰阴性菌,其中铜绿假单胞菌占10.00%;有25.00%的患者被检出真菌。对病原菌进行药敏试验,革兰阴性菌中铜绿假单胞菌对阿米卡星、舒巴坦钠、他唑巴坦、亚胺培南、美罗培南的敏感性均大于或等于83.30%;革兰阳性菌中表皮葡萄球菌和金黄色葡萄球菌对利奈唑安、万古霉素和环丙沙星的敏感性均大于或等于75.00%。结论眼科术后患者感染的病原菌,革兰阴性菌、革兰阳性菌和真菌均有,对常用青霉素等有较高的耐药性,但不同的病原菌都有各自敏感性较高的药物,临床上有针对性地、及时地选择有效的抗菌药物进行预防或治疗,从而降低眼科术后的感染率。     

中国北京地区犬真菌监测与药敏分析

目的 鉴定犬真菌微生物群(真菌区系),并进行药敏分析,为犬致病性真菌防控提供科学依据。方法 在中国的北京地区,共有55只没有疾病史的犬被取样。用真菌培养、PCR,基因克隆和测序技术,进行犬的真菌检测和鉴定。对所有真菌分离株进行药敏分析。结果 分离获得29株真菌,形态和分子鉴定确证这些真菌为黄曲霉、杂色曲霉、日本曲霉、卷枝毛霉、总状毛霉、多变根毛霉、壳青霉、产黄青霉、厚皮马拉塞霉菌、球毛壳霉、黄色蠕形霉、多喙茎点霉、尖孢镰刀菌、枝状枝孢菌、尖孢枝孢、极细枝孢霉、类星形毛孢子菌、阿萨希毛孢子菌、光滑念珠菌、库德里阿兹威毕赤酵母和东方伊萨酵母。结果表明,犬真菌种类比较丰富,获得真菌12属21种,曲霉属、毛霉属和枝孢菌属真菌在这些致病真菌中占主导地位。药敏分析结果显示:这些真菌对制霉菌素、咪康唑、沃尔康唑、特比萘芬和氟胞嘧啶等已经产生了耐药性。结论 联合使用真菌培养、PCR,基因克隆和测序技术能有效分析犬真菌。犬的真菌大多为人兽共患病病原体。研究结果为我国犬真菌监测提供参考数据,为致病性真菌的侵袭防制提供有效工具。     

In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp

The aim of the present study was to identify retrospectively trends in the species distributions and the susceptibility patterns of Aspergillus species causing fungal infections in Spanish medical centers from 2000 to 2002. The susceptibilities of 338 isolates to amphotericin B, itraconazole, and voriconazole were tested. Aspergillus fumigatus was the most common species (54.7%), followed by Aspergillus terreus (14.8%) and Aspergillus flavus (13.9%). Non-A. fumigatus species were encountered in 45.3% of the samples studied. The majority of Aspergillus isolates were obtained from respiratory tract specimens, followed by ear and skin samples. The geometric mean (GM) MIC of amphotericin B was 0.56 micro g/ml, and the amphotericin B MIC was >2 micro g/ml for 16 isolates (4.7%). Nine of them were A. terreus. The GM MIC of itraconazole was 0.37, and the itraconazole MIC was >4 micro g/ml for 12 (3.5%) isolates. The voriconazole MICs were also high for 8 of the 12 strains for which itraconazole MICs were high (voriconazole MIC range, 2 to 8 micro g/ml).     

Initial results from a longitudinal international surveillance programme for anidulafungin (2003)

OBJECTIVES: This longitudinal study evaluated the in vitro activity of anidulafungin against 880 clinical yeast isolates and 68 mould isolates from 64 medical centres in North America, Latin America and Europe. METHODS: MICs of anidulafungin, amphotericin B, 5-fluorocytosine, fluconazole, itraconazole, ketoconazole and voriconazole were determined using reference method (M27-A2) guidelines. The M38-A reference method was used for the filamentous fungi, including determination of minimum effective concentrations (MECs) of anidulafungin. RESULTS: Anidulafungin was more active when compared with fluconazole and itraconazole for Candida albicans (MIC(90), 0.06 mg/L), Candida tropicalis (MIC(90), 0.06 mg/L), Candida glabrata (MIC(90), 0.12 mg/L), Candida krusei (MIC(90), 0.06 mg/L) and Candida lusitaniae (MIC(90), 1 mg/L) as well as the less-often encountered yeast species. Anidulafungin was less active against Candida parapsilosis, Candida guilliermondii and Candida famata (MIC(50), 1-2 mg/L). Anidulafungin also exhibited excellent activity against all Aspergillus spp. (MEC(90), < or =0.03 mg/L). Anidulafungin was also evaluated comparing two end point reading criteria and two incubation intervals. Data indicate that longer incubation periods do not significantly influence overall MIC ranges. These international surveillance results for anidulafungin confirm the activity observed in studies of smaller numbers of isolates.     

呼吸机相关性肺炎病原菌分布及耐药性分析

目的 探讨呼吸机相关性肺炎(VAP)病原菌的分布特点及其耐药性,以指导临床合理选用抗生素.方法 回顾性分析78例VAP患者的病原菌分布及抗菌药物的耐药性.结果 78例VAP患者共分离出147株病原菌,其中革兰阴性菌94株(占66.0%),革兰阳性菌32株(占23.1%),真菌21株(占感染10.9%).革兰阴性菌中以铜绿假单胞菌、肺炎克雷伯菌、鲍曼不动杆菌、大肠埃希菌为主,革兰阳性菌中金黄色葡萄球菌和表皮葡萄球菌为主,白色假丝酵母菌及其他假丝酵母菌为真菌感染的主要致病菌.致病菌对常用抗菌药的耐药性普遍为高.结论 革兰阴性菌为VAP的主要病原菌,且耐药现象严重,在临床上应加强抗生素的管理,合理选用抗菌药物治疗VAP.     

国产伏立康唑对临床分离病原真菌体外抗菌活性研究

目的了解国产伏立康唑对北京和我国其他地区临床分离的常见病原真菌体外抗菌活性。方法分别参照CLSIM27-A2和M38-A方案测定伏立康唑对144株酵母和82株产孢丝状真菌的抗菌活性。受试菌株包括念珠菌114株（含氟康唑获得性耐药白念珠菌）、新型隐球菌20株、阿萨希毛孢子菌10株、曲霉62株（含伊曲康唑耐药曲霉及两性霉素B不敏感曲霉）、镰刀菌10株、尖端赛多孢菌10株。结果伏立康唑对念珠菌（不包括氟康唑耐药和剂量依赖敏感白念珠菌）、新型隐球菌、阿萨希毛孢子菌的MIC50≤0．5mg／L、MIC90≤1mg／L；而对氟康唑获得性耐药白念珠菌MIC50和MIC90均〉16mg／L。对曲霉、尖端赛多孢菌的MIC50≤1mg／L、MIC90≤2mg／L，对镰刀菌的MIC50和MIC90分别为4mg／L和〉16mg／L。结论伏立康唑对多数酵母有较强的体外抗菌活性，尤其是对克柔念珠菌和光滑念珠菌等氟康唑天然耐药菌株。该药对多数产孢丝状真菌也有较好的体外抗菌作用，包括伊曲康唑耐药及两性霉素B不敏感的曲霉以及对多种抗真菌药物耐药的尖端赛多孢菌；但其对氟康唑获得性耐药白念珠菌有一定交叉耐药。